Frosty,
Thanks for the reply. I respect your perspective, but I would argue a couple points:
1. Authorized shares are not issued shares. They simply give management the option to issue shares if/when they need to. They’re shareholders too, so they won’t issue any of the authorized shares unless or until it’s necessary.
2. Our fuddy buddies scream about big industry partnerships, but those kinds of deals would be nearly impossible unless the company has the flexibility of readily available authorized shares…
I’m guessing big partners don’t like situations where they have to say…
“We want a 20% equity stake, but your shareholder vote won’t happen for 6–7 months.”
Yes, it is common & often necessary for a clinical-stage biotech to have a large pool of authorized shares on hand to preserve the possibility of major partnerships, equity-based collaborations, or acquisition friendly structures. NWBO increasing its authorized shares is consistent with preparing for those possibilities.
Bullish
Market Data 
Markets 
AI
